M

MacroGenics
D

MGNX

1.76000
USD
0.07
(4.14%)
مغلق
حجم التداول
25,866
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
111,038,968
أصول ذات صلة
ABBV
ABBV
5.160
(2.67%)
198.440 USD
AZN
AZN
1.940
(2.75%)
72.440 USD
BMY
BMY
1.000
(2.02%)
50.560 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
N
NKTR
-0.02630
(-3.38%)
0.75210 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
المزيد
الأخبار المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.